Malignant melanoma in early Parkinson's disease: The DATATOP trial
Identifieur interne : 002D55 ( Main/Exploration ); précédent : 002D54; suivant : 002D56Malignant melanoma in early Parkinson's disease: The DATATOP trial
Auteurs : Radu Constantinescu [États-Unis] ; Megan Romer [États-Unis] ; Karl Kieburtz [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-04-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Cohort Studies, Comorbidity, Cross-Sectional Studies, Female, Humans, Incidence, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Malignant melanoma, Melanoma (epidemiology), Middle Aged, Multicenter Studies as Topic, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson disease, Parkinson's disease, Randomized Controlled Trials as Topic, Reference Values, Retrospective Studies, Skin Neoplasms (epidemiology), levodopa.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- epidemiology : Melanoma, Parkinson Disease, Skin Neoplasms.
- Adult, Aged, Aged, 80 and over, Cohort Studies, Comorbidity, Cross-Sectional Studies, Female, Humans, Incidence, Male, Middle Aged, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Reference Values, Retrospective Studies.
Abstract
The available epidemiological data on the incidence of malignant melanoma in Parkinson's disease are contradictory. The role of levodopa therapy in this context has been debated. We identified all known cases of malignant melanoma (N = 5) in the DATATOP clinical trial cohort and compared that to published expected values (N = 1.5) for a standard healthy population. The standardized event ratio was 3.3 (95% confidence interval, 1.1–7.8), indicating that incidence of malignant melanoma was higher than expected. We found no association between levodopa therapy and the incidence of melanoma. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21273
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003647
- to stream Istex, to step Curation: 003647
- to stream Istex, to step Checkpoint: 001863
- to stream PubMed, to step Corpus: 002803
- to stream PubMed, to step Curation: 002803
- to stream PubMed, to step Checkpoint: 002727
- to stream Ncbi, to step Merge: 001B36
- to stream Ncbi, to step Curation: 001B36
- to stream Ncbi, to step Checkpoint: 001B36
- to stream Main, to step Merge: 003C77
- to stream PascalFrancis, to step Corpus: 001714
- to stream PascalFrancis, to step Curation: 001607
- to stream PascalFrancis, to step Checkpoint: 001600
- to stream Main, to step Merge: 004190
- to stream Main, to step Curation: 002D55
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Malignant melanoma in early Parkinson's disease: The DATATOP trial</title><author><name sortKey="Constantinescu, Radu" sort="Constantinescu, Radu" uniqKey="Constantinescu R" first="Radu" last="Constantinescu">Radu Constantinescu</name></author><author><name sortKey="Romer, Megan" sort="Romer, Megan" uniqKey="Romer M" first="Megan" last="Romer">Megan Romer</name></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:99EF13754140EE85799959C5BE8A9F31E5EEEADB</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21273</idno><idno type="url">https://api.istex.fr/document/99EF13754140EE85799959C5BE8A9F31E5EEEADB/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003647</idno><idno type="wicri:Area/Istex/Curation">003647</idno><idno type="wicri:Area/Istex/Checkpoint">001863</idno><idno type="wicri:doubleKey">0885-3185:2007:Constantinescu R:malignant:melanoma:in</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17373726</idno><idno type="wicri:Area/PubMed/Corpus">002803</idno><idno type="wicri:Area/PubMed/Curation">002803</idno><idno type="wicri:Area/PubMed/Checkpoint">002727</idno><idno type="wicri:Area/Ncbi/Merge">001B36</idno><idno type="wicri:Area/Ncbi/Curation">001B36</idno><idno type="wicri:Area/Ncbi/Checkpoint">001B36</idno><idno type="wicri:doubleKey">0885-3185:2007:Constantinescu R:malignant:melanoma:in</idno><idno type="wicri:Area/Main/Merge">003C77</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:07-0263043</idno><idno type="wicri:Area/PascalFrancis/Corpus">001714</idno><idno type="wicri:Area/PascalFrancis/Curation">001607</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001600</idno><idno type="wicri:doubleKey">0885-3185:2007:Constantinescu R:malignant:melanoma:in</idno><idno type="wicri:Area/Main/Merge">004190</idno><idno type="wicri:Area/Main/Curation">002D55</idno><idno type="wicri:Area/Main/Exploration">002D55</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Malignant melanoma in early Parkinson's disease: The DATATOP trial</title><author><name sortKey="Constantinescu, Radu" sort="Constantinescu, Radu" uniqKey="Constantinescu R" first="Radu" last="Constantinescu">Radu Constantinescu</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester Medical Center, Rochester New York</wicri:regionArea><wicri:noRegion>Rochester New York</wicri:noRegion></affiliation></author><author><name sortKey="Romer, Megan" sort="Romer, Megan" uniqKey="Romer M" first="Megan" last="Romer">Megan Romer</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester Medical Center, Rochester New York</wicri:regionArea><wicri:noRegion>Rochester New York</wicri:noRegion></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester Medical Center, Rochester New York</wicri:regionArea><wicri:noRegion>Rochester New York</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-04-15">2007-04-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="720">720</biblScope><biblScope unit="page" to="722">722</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">99EF13754140EE85799959C5BE8A9F31E5EEEADB</idno><idno type="DOI">10.1002/mds.21273</idno><idno type="ArticleID">MDS21273</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Cohort Studies</term><term>Comorbidity</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Incidence</term><term>Levodopa</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Malignant melanoma</term><term>Melanoma (epidemiology)</term><term>Middle Aged</term><term>Multicenter Studies as Topic</term><term>Nervous system diseases</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Randomized Controlled Trials as Topic</term><term>Reference Values</term><term>Retrospective Studies</term><term>Skin Neoplasms (epidemiology)</term><term>levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Melanoma</term><term>Parkinson Disease</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Cohort Studies</term><term>Comorbidity</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Middle Aged</term><term>Multicenter Studies as Topic</term><term>Randomized Controlled Trials as Topic</term><term>Reference Values</term><term>Retrospective Studies</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Lévodopa</term><term>Mélanome malin</term><term>Parkinson maladie</term><term>Système nerveux pathologie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The available epidemiological data on the incidence of malignant melanoma in Parkinson's disease are contradictory. The role of levodopa therapy in this context has been debated. We identified all known cases of malignant melanoma (N = 5) in the DATATOP clinical trial cohort and compared that to published expected values (N = 1.5) for a standard healthy population. The standardized event ratio was 3.3 (95% confidence interval, 1.1–7.8), indicating that incidence of malignant melanoma was higher than expected. We found no association between levodopa therapy and the incidence of melanoma. © 2007 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Constantinescu, Radu" sort="Constantinescu, Radu" uniqKey="Constantinescu R" first="Radu" last="Constantinescu">Radu Constantinescu</name></noRegion><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><name sortKey="Romer, Megan" sort="Romer, Megan" uniqKey="Romer M" first="Megan" last="Romer">Megan Romer</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:99EF13754140EE85799959C5BE8A9F31E5EEEADB
|texte= Malignant melanoma in early Parkinson's disease: The DATATOP trial
}}
| This area was generated with Dilib version V0.6.23. |  |